A5023890444- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Occupational and environmental lung diseases
- Brain Metastases and Treatment
- Frailty in Older Adults
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Tracheal and airway disorders
- Salivary Gland Tumors Diagnosis and Treatment
- Palliative Care and End-of-Life Issues
- Medical Imaging Techniques and Applications
- Histone Deacetylase Inhibitors Research
- Peptidase Inhibition and Analysis
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging and Pathology Studies
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- Pleural and Pulmonary Diseases
Yokohama Municipal Citizen's Hospital
2016-2025
Nippon Medical School
2008-2012
Tokyo Metropolitan Komagome Hospital
2009-2010
Abstract Introduction The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its significance patients with small-cell lung cancer (SCLC) treated immune checkpoint inhibitors (ICIs) remains unclear. In this study, we evaluated the impact of SII SCLC after ICI use. Methods Of 62 who received chemoimmunotherapy at our institution between September 2019 and July 2024, retrospectively analyzed 36 subsequently maintenance...
The G8 questionnaire is a quick and easy-to-use screening tool. Several studies reported that the had high sensitivity for predicting abnormalities in full comprehensive geriatric assessment predicted functional decline survival elderly cancer patients. present study aimed to evaluate role of clinical outcomes overall (OS) patients with lung cancer, who received chemotherapy or chemoradiotherapy. data 101 aged ≥70 years, were hospitalized between September 2011 August 2014, analyzed. Of...
No study has directly compared the outcomes of surgery and concurrent chemoradiotherapy (cCRT) in patients with stage III non-small cell lung cancer (NSCLC) to date. This aimed compare treatment efficacy complete resection definitive cCRT. Patients were recruited this retrospective from Yokohama Municipal Citizens' Hospital between January 2013 December 2022. We analyzed pathological NSCLC who underwent surgical those clinical Propensity score matching was performed balance baseline...
Abstract Purpose: The addition of cytotoxic chemotherapy to immune-checkpoint inhibitor (ICI) may enhance antitumor effects. We conducted an open-label randomized phase II/III study evaluate nivolumab + docetaxel combination therapy in comparison with monotherapy for previously treated ICI-naïve non–small cell lung cancer (NSCLC). Patients and Methods: primary endpoint the III was overall survival (OS), secondary endpoints included progression-free (PFS), response rate (ORR), toxicity. As...
ObjectivesCisplatin plus irinotecan has been considered as the standard therapy in younger (<70 years old) patients for extensive-disease small-cell lung cancer (ED-SCLC) Japan. However, there is a lack of high-quality evidence use elderly with ED-SCLC. This study aimed to demonstrate that carboplatin (CI) improves overall survival (OS) ED-SCLC.Materials and methodsThis was randomized Phase II/III trial which enrolled Patients were CI or etoposide (CE) arm 1:1 ratio. The CE group...
Abstract Cisplatin‐based chemoradiotherapy is considered standard treatment for unresectable locally advanced non‐small‐cell lung cancer (LA‐NSCLC). This study examined two regimens of chemotherapy in concurrent chemoradiation. Eligible patients with unresectable, radically irradible LA‐NSCLC were randomized to either the SP (S‐1 and cisplatin) or DP (docetaxel arms thoracic radiotherapy 60 Gy, comprising 2 Gy per daily fraction. The primary endpoint was overall survival (OS) rate at years...
Background Pleurodesis is the standard of care for non‐small cell lung cancer (NSCLC) patients with symptomatic malignant pleural effusion (MPE). However, there no management MPE uncontrolled by pleurodesis. Most unsuccessful control are unable to receive effective chemotherapy. Vascular endothelial growth factor (VEGF) plays an important role in pathogenesis MPE. This multicenter, phase II study investigated effects bevacizumab plus chemotherapy nonsquamous NSCLC Methods Nonsquamous...
Abstract Background. Prior supplementation with folic acid and vitamin B12 is required to reduce pemetrexed therapy toxicity; the recommended lead-in time at least 7 days. On basis of previous pharmacokinetic clinical studies, we hypothesized that could be shortened 24 hours, enabling earlier commencement standard chemotherapy; thus, planned first prospective trial this regimen. Methods. Patients advanced nonsquamous non-small cell lung cancer who had not previously received cytotoxic...
Remdesivir has been shown to reduce recovery time and mortality among patients with coronavirus disease 2019 (COVID-19). However, data regarding the efficacy safety of remdesivir use are limited in Japan. We conducted a single-center retrospective cohort study at Yokohama Municipal Citizen's Hospital, Kanagawa, Patients COVID-19 pneumonia treated were included. The onset acute pancreatitis increased pancreatic enzyme levels clinical, laboratory, treatment, outcome collected analyzed. A total...
Enzastaurin, an oral serine-threonine kinase inhibitor, was initially developed as ATP-competitive selective inhibitor against protein Cβ. However, the mechanism by which enzastaurin contributes to tumourigenesis remains unclear.We analysed anti-tumour effects of in 22 lung cancer cell lines ascertain potential for enzastaurin-based treatment cancer. To identify molecules or signalling pathways associated with this sensitivity, we conducted a gene, receptor tyrosine kinases phosphorylation...
Abstract Background Granulocyte colony-stimulating factor (G-CSF)-producing lung cancer induces severe inflammation and a high white blood cell (WBC) count is associated with poor prognosis. A recent case of G-CSF-producing adenocarcinoma showed expression programmed death ligand 1 (PD-L1) was treated pembrolizumab as first-line therapy, which extremely effective. We hypothesized that cancers are PD-L1 expression. Methods This retrospective study included patients diagnosed at Yokohama...
Durvalumab consolidation after chemoradiotherapy for stage III non-small cell lung cancer (NSCLC) has become the standard of care. Single-center results were examined treatment outcomes and patterns pneumonitis in clinical practice. Patients with NSCLC who underwent at our institution (n = 150) included. The patients treated durvalumab (Group D, n 69) or alone N, 81). overall survival (OS), progression-free (PFS), incidence risk factors 12-month grade ≥ 2 (G2) investigated. Two-year OS rates...
Abstract Background The relationship between epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) resistance, including osimertinib, and programmed cell death‐ligand 1 (PD‐L1) expression status in EGFR ‐mutated non‐small lung carcinoma (NSCLC) remains unclear. Patients Methods We retrospectively analyzed 64 patients with unresectable advanced or metastatic NSCLC carrying exon 19 deletions (ex19del) 21 L858R substitutions (L858R) who received osimertinib as the first‐line...
Abstract Background Cold agglutination syndrome is a subtype of autoimmune hemolytic anemia. The condition referred to as “cold” because the antibodies become active and induce hemolysis at cold temperatures, typically 3–4 °C, which not always case in other kinds Whereas primary may occur absence underlying conditions, secondary associated with presence infections, including coronavirus disease 2019. Case presentation We report 69-year-old Japanese woman periodontitis who was our hospital...
The role of irinotecan for elderly patients with LD-SCLC has been unclear, and the timing TRT combined chemotherapy not fully evaluated. Patients aged > 70 years untreated, measurable, LD-SCLC, performance status (PS) 0–2, adequate organ function were eligible. Treatment consisted induction carboplatin on day 1 days 8, every 21 4 cycles, sequential (54Gy in 27 fractions). Carboplatin doses based AUC 5 (levels 2, respectively), a fixed dose (50 mg/m2). Primary objective phase II study was...
Malignant pericardial mesothelioma (MPM) is a rare tumour that arises from the mesothelial cells of pericardium. No standard treatment has been established owing to poor response; therefore, MPM prognosis. We herein report case in 70-year-old man was diagnosed immunohistopathologically using cell block sections fluid and which long-term survival for more than 3 years achieved with only periodic drainage. Immunohistopathological staining investigations, especially BRCA1-associated protein 1...
Compared with standard chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. However, data comparing the efficacies of different EGFR-TKIs, especially regarding presence brain metastasis, lacking.EGFR-TKI naive recurrent or stage IIIB/IV NSCLC mutations, excluding resistance were enrolled this study. We retrospectively determined progression-free survival (PFS)...
ObjectiveThe role of platinum agents plus irinotecan has been unclear for elderly patients with extensive disease small-cell lung cancer. We conducted a feasibility study to evaluate the safety and efficacy carboplatin in preparation planned Phase III study.
Summary Purpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in Japanese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) previously treated EGFR-TKI. Methods This was an open-label, non-randomized, multi-center, dose escalation, phase I study conducted three phases (dose expansion, extension phases)....